Business
Dario Introduces GLP-1 Behavior Change Program to Help Achieve Weight Loss Goals and Better Overall Health Outcomes
New program delivers whole health behavior change program to improve member health and deliver valuable insights to Dario's partners NEW YORK, Aug. 2, 2023
About this update from Dariohealth Corp.
[{"type":"text","content":"New program delivers whole health behavior change program to improve member health and deliver valuable insights to Dario's partners \nNEW YORK, Aug. 2, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) (\"Dario\" or the \"Company\"), a leader in the global digital health market, announced a new program today to deliver tailored behavior change support for individuals using GLP-1s and other anti-obesity drugs. The new program will help members realize the transformational power of these new medications while improving overall health and potentially help Dario's partners gain better insights on the impact across their populations.\n \nConsumers are driving a surge in demand for GLP-1s and employers and payers are working to solve for access with a limited understanding of broader clinical and financial implications. Early research highlights one key challenge: long-term adoption needed to realize the full benefits of the medications for both patients and payers, as two out of three people stop taking the drug in the first year.\nGLP-1s are U.S. Food and Drug Administration-approved for use in adults with certain related chronic conditions when used in conjunction with a reduced calorie diet and increased physical activity. Dario's solution is designed to help people successfully realize their weight loss goals alongside these medications and beyond their prescription by focusing on a whole health approach. Dario's proven combination of innovative technologies and human support is proven to impact multiple chronic conditions by focusing on changing the underlying health behaviors.\nBillions of data insights from Dario's decade of direct-to-consumer experience are used to drive highly personalized journeys focused on driving healthier lifestyle behaviors, and the new GLP-1 program builds on this approach to deliver long-term behavior change. Members using a GLP-1 or other anti-obesity medication who enroll in Dario's cardiometabolic solution will receive a highly personalized experience optimizing digital coaching and professional human support to improve overall health.\nMembers will also have access to Dario's new Medication Cabinet, a digital tool developed through collaboration with the Company's strategic partner, Sanofi US, that allows members to track their medication adherence. The new feature will help members manage t...